Lactobacillus jensenii

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Lactobacillus jensenii is a Gram-positive, non-spore-forming, facultatively anaerobic, rod-shaped bacterium. It has been detected in at least 4 gut microbiome compilation studies or metastudies. The DNA G+C content is 35–37%. Lactobacillus jensenii is likely to be transient and not a long-term gut coloniser. (Gasser1970; Hammes2011Bergey; Rossi2016)



  • This organism has been recovered from clinical sources (vagina, kidney, cervix, urine) and human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: opportunistic in immunocompromised patients). Is a rare opportunistic pathogen. Likely to be transient and not a long-term gut commensal.
    • GENERAL CHARACTERISTICS (Gasser1970); (Hammes2011Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; arginine;
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 15℃; grows at 45℃;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; mannose; amygdalin; aesculin; cellubiose; maltose; sucrose; trehalose; arbutin; salicin;
  • Active enzymes:
  • Ala arylamidase; acid phosphatase; β-glucosidase; Leu arylamidase;
    • SPECIAL FEATURES (Gasser1970); (Hammes2011Bergey);
    Character Response
  • ✓
  • Metabolites produced:
  • lactate;
  • ✗
  • Metabolites not produced:
  • H₂S; indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Tyrrell2012); (Goldstein2006c); (Goldstein2005); (Citron2003); (Citron2001);
    Class Active Resistant
  • Penicillins:
  • ampicillin; ampicillin-sulbactam; imipenem; meropenem; penicillin; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefoxitin;
  • Macrolides:
  • pristinamycin; quinupristin-dalfopristin;
  • Tetracyclines:
  • doxycycline; tigecycline;
  • Quinolines:
  • levofloxacin; moxifloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; pristinamycin;

  • Carlsson, J., & Gothefors, L. (1975). Transmission of Lactobacillus jensenii and Lactobacillus acidophilus from mother to child at time of delivery. Journal of Clinical Microbiology, 1(2), 124–128.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Lactobacillales Family:  Lactobacillaceae Genus:  Lactobacillus Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Morphology:  Rod
    Health:  Unknown
    Source:  clinical sources (vagina, kidney, cervix, urine) and human faeces
    DNA G+C(%):  35–37
    Low T(℃):  15(neg)
    High T(℃):  45(+)
    		Aesculin:  + Urea:  neg Gelatin:  neg Casein:  neg Arginine:  + Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg D-Arabinose:  neg L-Arabinose:  neg Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  neg Glucose:  + Mannose:  + D-Lyxose:  neg Rhamnose:  neg Ribose:  vr Sorbose:  neg D-Tagatose:  neg Xylose:  neg L-Xylose:  neg Cellubiose:  + Gentiobiose:  vr Lactose:  neg Maltose:  + Melezitose:  neg Melibiose:  neg Sucrose:  + Trehalose:  + Turanose:  neg Amygdalin:  + Dextrin:  neg Aesculin:  + Glycogen:  neg Inulin:  neg Starch:  vr Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Xylitol:  neg Arbutin:  + Gluconate:  neg 2-Ketogluconate:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  vr Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  vr Salicin:  +
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  vr Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  vr β-Galactosidase:  neg α-Glucosidase:  vr β-Glucosidase:  + β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  vr GluDC:  neg AlanineAA:  + AlaPheProAA:  vr GluGluAA:  neg GlyAA:  vr LeuAA:  + LeuGlyAA:  neg PyrrolidAA:  vr AlkalineP:  neg AcidP:  + Esterase(C4):  vr EstLip(C8):  vr Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Lactate:  + H2S:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  S(MIC50): 0.128, MIC90: 0.5, RNG: (0.03-1)
    amp-sulb:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.25-0.5)
    penicillin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.06–1)
    penicillin_G:  S(MIC50): 0.25, MIC90: 1, RNG: (0.02-4)
    piper-taz:  S(MIC50): 0.25, MIC90: 1, RNG: (≤0.03-1)
    imipenem:  S(MIC50): 0.062, MIC90: 0.25, RNG: (0.06-0.5)
    meropenem:  S(MIC50): 0.062, MIC90: 0.25, RNG: (0.06-0.5)
    cefoxitin:  R(MIC50): 64, MIC90: >128, RNG: (0.06–>128)
    azithromycin:  Var(MIC50): 2, MIC90: >32, RNG: (0.06–>32)
    erythromycin:  Var(MIC50): 1, MIC90: >32, RNG: (0.06–>32)
    clarithromycin:  Var(MIC50): 0.5, MIC90: >32, RNG: (0.06–>32)
    pristinamycin:  S(MIC50): 0.12, MIC90: 0.25, RNG: (0.03–2)
    quin-dalf:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125-4)
    roxithromycin:  Var(MIC50): 2, MIC90: >32, RNG: (0.06–>32)
    telithromycin:  Var(MIC50): 0.06, MIC90: >32, RNG: (0.06–>32)
    linezolid:  S(MIC50): 4, MIC90: 8, RNG: (0.5–16)
    ciprofloxacin:  Var(MIC50): 1, MIC90: 16, RNG: (0.12-16)
    levofloxacin:  S(MIC50): 2, MIC90: 4, RNG: (0.125–8)
    moxifloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.125–8)
    ofloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (0.12-8)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 4, MIC90: 8, RNG: (0.125–16)
    tigecycline:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–1)
    dalbavancin:  Var(MIC50): >0.5, MIC90: >32, RNG: (0.06->32)
    teicoplanin:  Var(MIC50): 1, MIC90: >64, RNG: (0.06–>64)
    vancomycin:  S(MIC50): 1, MIC90: 2, RNG: (0.25–4.0)
    bacitracin:  Var(MIC50): 8, MIC90: 128, RNG: (0.5–>128)
    metronidazole:  R(MIC50): >32, MIC90: >32, RNG: (0.5->32)
    clindamycin:  S(MIC50): 0.125, MIC90: 2, RNG: (0.02->32)
    daptomycin:  Var(MIC50): 1, MIC90: 16, RNG: (≤0.03-32)

    References

    SPECIFIC REFERENCES FOR LACTOBACILLUS JENSENII
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Zheng2020 - A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae.
  • Gasser1970 - Lactobacillus jensenii sp. nov., a New Representative of the Subgenus Thermobacterium.
  • Hammes2011Bergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Lactobacillaceae, Genus I. Lactobacillus
  • Rossi2016 - Mining metagenomic whole genome sequences revealed subdominant but constant Lactobacillus population in the human gut microbiota.
  • Gryp2020 - Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Citron2001 - Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR LACTOBACILLUS JENSENII
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR LACTOBACILLUS JENSENII
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021